Table 3 The incremental comparison of expected life years, QALYs, costs, and ICERs for five screening strategies for heart failure in patients with type 2 diabetes of 60 years or older
From: Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes
Strategy | 0 No screening | 1 EMR symptoms | 2 EMR symptoms Physical Exam | 3 EMR symptoms Physical exam NTproBNP | 4 EMR symptoms Physical exam NTproBNP ECG | 5 Echocardiography |
|---|---|---|---|---|---|---|
Life expectancy (years) | ||||||
 Men | 14.726 | 14.742 | 14.742 | 14.742 | 14.742 | 14.742 |
 Women | 16.830 | 16.851 | 16.851 | 16.851 | 16.851 | 16.852 |
QALY expectancy (years) | ||||||
 Men | 12.345 | 12.477 | 12.477 | 12.477 | 12.477 | 12.479 |
 Women | 14.047 | 14.215 | 14.215 | 14.216 | 14.215 | 14.217 |
Expected costs pp (euros) | ||||||
 Men | €6795 | €7605 | €7611 | €7625 | €7642 | €7667 |
 Women | €5024 | €6086 | €6093 | €6107 | €6125 | €6152 |
Strategy comparison | NA | 1 vs 0 | 2 vs 1 | 3 vs 1 | 4 vs 1 | 5 vs 1 |
Additional QALYs to comparator | ||||||
 Men | NA | 0.132 | 0.000 | 0.000 | 0.000 | 0.002 |
 Women | NA | 0.168 | 0.000 | 0.000 | 0.000 | 0.002 |
Additional costs to comparator | ||||||
 Men | NA | €810 | NA | NA | NA | €62 |
 Women | NA | €1063 | NA | NA | NA | €66 |
ICER | ||||||
 Men | NA | €6115a | Dominated | Dominated | Dominated | €29,100 |
 Women | NA | €6318a | Dominated | Dominated | Dominated | €39,326 |